Top-News
Biotechnologie USA

Poseida Therapeutics Aktie

Aktie
WKN:  A2PEYK ISIN:  US73730P1084 US-Symbol:  PSTX
8,985 €
-0,08 €
-0,88%
12.12.24
Handeln Depot/Watchlist
Aktienanzahl *
95,62 Mio.
Marktkapitalisierung *
848,95 Mio. €
Streubesitz
13,88%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.12.2023

Poseida Therapeutics News

09.12.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders PR Newswire
09.12.24 - PR Newswire
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of ...
03.12.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, SUM, FVNNU, HUDA on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, SUM, FVNNU, HUDA on Behalf of Shareholders PR Newswire
27.11.24 - PR Newswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX PR Newswire
26.11.24 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX PR Newswire
26.11.24 - wallstreetONLINE Redaktion
Pharmariese greift zu: Diese Biotech-Aktie hat sich an einem Tag verdreifacht
Für bis zu 1,5 Milliarden US-Dollar kauft Roche das in San Diego ansässige Biotech-​Unternehmen Poseida Therapeutics. Die Aktie startet durch und sorgt für Begeisterung bei ...
26.11.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CTV, AUB on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CTV, AUB on Behalf of Shareholders PR Newswire
26.11.24 - PR Newswire
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. PR Newswire
14.11.24 - PR Newswire
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline PR Newswire
11.11.24 - PR Newswire
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire
07.11.24 - PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 PR Newswire
05.11.24 - PR Newswire
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 PR Newswire
24.10.24 - PR Newswire
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema PR Newswire
17.10.24 - PR Newswire
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche PR Newswire
03.10.24 - PR Newswire
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 PR Newswire
27.09.24 - PR Newswire
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated ...
16.09.24 - PR Newswire
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma PR ...
05.09.24 - PR Newswire
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st ...
04.09.24 - PR Newswire
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma PR Newswire
29.08.24 - PR Newswire
Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Therapeutics to Present at Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
13.12.24
TRADING Insights Webinar vom 12.12.24
Themen: Aktienmarkt-​Entwicklung, Soft-​Commodities, wie Baumwolle, Kakao, Orangensaft, aber auch die ... Mehr »